Fortress Biotech Inc SEC Filings

Welcome to our dedicated page for Fortress Biotech SEC filings (Ticker: FBIOP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

The Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (FBIOP) SEC filings page provides access to regulatory documents filed by Fortress Biotech, Inc. with the U.S. Securities and Exchange Commission. According to Form 8-K filings, FBIOP is the trading symbol for the company’s 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock, which is registered under Section 12(b) of the Securities Exchange Act of 1934 and listed on the Nasdaq Capital Market alongside the common stock (FBIO).

In the available Form 8-K filings, Fortress Biotech reports material events such as quarterly financial results, annual meeting voting outcomes and other corporate updates. These filings identify both the common stock and the 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock in the table of securities registered pursuant to Section 12(b), confirming their listing on the Nasdaq Capital Market. The filings also indicate that Fortress Biotech is incorporated in Delaware.

Within the company’s financial statements, which are referenced in press releases and may be included in periodic reports, the 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock appears as cumulative redeemable perpetual preferred stock with a designated number of Series A shares issued and outstanding and a stated liquidation value per share. These disclosures help investors understand how the preferred stock fits into Fortress Biotech’s capital structure alongside common equity, additional paid-in capital, accumulated deficit and non-controlling interests.

On this page, users can review SEC filings such as Form 8-K that mention FBIOP and Fortress Biotech’s preferred stock, as well as filings that discuss results of operations, financial condition and stockholder votes. AI-powered tools can assist in summarizing lengthy filings and highlighting sections that reference the 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock, the company’s registered securities table and key financial statement line items. This allows readers to quickly identify how Fortress Biotech describes FBIOP within its official regulatory disclosures and how the preferred stock relates to the company’s overall financial reporting.